Posted by linkadge on September 8, 2010, at 21:28:47
In reply to Re: Polypharmacy Common But Is More Better?, posted by linkadge on September 8, 2010, at 21:23:58
Basically this suggests that if you *don't* have TRD (or havn't specifically failed a the given treatment), then monotherapy is better.
It doesn't show that once you fail an initial treatment, that addding a secondary agent doesn't result in a higher remission rates.
In other words, the study is flawed because its not focusing on TRD patients (ie those whom you would expect to receive polypharmacy).
Linkadge
poster:linkadge
thread:961695
URL: http://www.dr-bob.org/babble/20100908/msgs/961739.html